


BNT411

| | |
|--------------------|---|
| Cat. No.: | HY-160715 |
| CAS No.: | 2296821-50-4 |
| Molecular Formula: | C ₂₄ H ₃₃ N ₅ O ₃ |
| Molecular Weight: | 439.55 |
| Target: | Toll-like Receptor (TLR) |
| Pathway: | Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------|---|
| Description | BNT411 is a selective TLR7 agonist that can induce the release of IFN α both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) ^[1] . |
| In Vivo | BNT411 (3 mg/kg; i.v.; 8 times with 4 to 5 days interval) demonstrates antitumor activity in mouse tumor models ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Ugur Sahin, et al. Tlr7 agonist and combinations for cancer treatment. WIPO. WO2023083868. 2023-05-19

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA